Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
Evogene (NASDAQ: EVGN) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will discuss results in a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time).
Investors must register in advance to attend and the full webcast will be posted on the company's website a few days after the call. Registration link: https://www.veidan-conferencing.com/evogene.
Details
News Market Reaction – EVGN
On Feb 19, the day this news came out, EVGN closed 5.57% below the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- Results release date
- March 5, 2026
- Q4 and full-year 2025 financial results release and conference call
- H1 2025 revenue
- $3.2 million
- H1 2025 vs H1 2024 revenue ($2.3 million)
- H1 2024 revenue
- $2.3 million
- Prior-year comparison for H1 2025 revenue
- H1 2025 operating expenses
- $7.7 million
- Down from $11.1 million in H1 2024
- Sale proceeds
- $18.71 million
- Sale of Lavie Bio assets and MicroBoost AI for Ag to ICL
- Q1 2025 revenue
- $2.4 million
- Down from $4.2 million in Q1 2024
- Q1 2024 revenue
- $4.2 million
- Prior-year comparison for Q1 2025 revenue
- Cash position
- $11.7 million
- Cash as of June 30, 2025
Previous Earnings Reports
-
Announcement of Q3 2025 results date and conference call details.
-
Reported higher H1 2025 revenue and lower operating expenses year over year.
-
Set Q2 2025 results release date and investor call logistics.
-
Reported Q1 2025 revenue decline versus 2024 despite cost reductions.
-
Announced Q1 2025 results timing and related conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Zoom conference call scheduled for March 5, 2026, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.
At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.
Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation".
Learn more at: www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-fourth-quarter-and-full-year-2025-financial-results-release-302692436.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.